The amlodipine besylate market was valued at USD 1,049.6 Mn by 2019. Rising prevalence of hypertension worldwide primarily drives the amlodipine besylate market growth. Additionally, the effective implementation of treatment guidelines pertaining to coronary artery disease further accentuates the market growth.

According to the information furnished by the World Health Organization (WHO), it is estimated that cardiovascular diseases are the number 1 cause of death globally, in which three-quarters of the victims are residing in the low and middle-income countries. Amlodipine besylate belongs to the class of calcium channel blockers in due to its strong affinity for cell membranes modulating the calcium influx by inhibiting selected calcium channel membranes. These pharmacodynamic effects allow it to have a long-lasting effect and low dosing frequency.

The major segments related to the amlodipine besylate market are: 

By Clinical Application (2017–2027; US$ Mn)

Hypertension

Chronic Stable Angina

Others

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

• The intention of the study is to give a comprehensive outlook of the global amlodipine besylate market
• The overall segmentation of the amlodipine besylate market, by clinical application, distribution channel, and geography is minutely studied. Hypertension and hospital pharmacy are dominating the clinical application and distribution channel segments respectively
• Rising prevalence of  hypertension worldwide
• Significant increase in the formulation development of generic drug combination for the treatment of coronary artery disease across the globe

Report gist?

• The study of the global amlodipine besylate market includes qualitative analysis of factors such as drivers, restraints, and opportunities
• The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of clinical application and distribution channel and categorization of the same at the geography level
• This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning 

Significant customers?

• This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of amlodipine besylate owing to the rising prevalence of hypertension worldwide
• The report will benefit formulation scientist actively engaged in the development of drug combination containing amlodipine besylate for the treatment of coronary artery disease across the globe
• Managers with financial institutions looking to publish recent and forecasted statistics pertaining to amlodipine besylate market
• Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Hypertension is spearheading the clinical application segment for the amlodipine besylate market. Increasing consumption of alcohol, tobacco products, junk foods, a sedentary lifestyle is associated with the disease etiology of hypertension worldwide. As per the latest research citings presented by the World Health Organization (WHO), approximately 1.13 people across the globe are suffering from hypertension. Chronic stable angina will be showcasing rampant market growth during the forecast period on account of the growing incidence of coronary artery disease worldwide. According to the research information provided by the Lancet Journal, it is estimated that 18% of the individuals suffering from coronary artery disease further suffer from angina attacks.

Hospital pharmacy is presently leading the distribution channel segment for the amlodipine besylate market. The drug is associated with side effects such as swelling, dizziness, drowsiness, nausea, etc., which makes it necessary for accurate drug dispensing under the medical supervision of a hospital pharmacist. Retail pharmacy is expected to garner magnificent market performance in the near future owing to the flourishing generic drugs market and capacity to cater to the medicinal requirements of households residing in the remote locations.

North America is the clear leader in the geography segment for the amlodipine besylate market. The rising prevalence of coronary artery disease primarily drives market growth in the region. According to the latest research citings provided by the Center for Disease Control and Prevention (CDC), approximately 9.8 million Americans suffer from angina pectoris. Additionally, the nurturing environment provided by the USFDA for the sale and distribution of amlodipine besylate drug formulations and favorable reimbursement scenario associated with the medicinal use of the drug together accentuates the market growth in the region. Europe is considered as the second-largest regional segment on account of the growing incidence of coronary disease in the young adult population residing in the region. Furthermore, the domicile of key players such as Merck KGaA, Sandoz, Inc., Teva Pharmaceutical Industries Limited., Mylan Pharmaceutical Industries Limited, etc further propels the market growth in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for the amlodipine besylate market on account of the flourishing generic drugs market and effective implementation of the treatment guidelines pertaining to the management of hypertension.